Health
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
RAHWAY, N.J., February 27, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer reg
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/8eb769ba2d92c371f856ccb19f65ad94"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/s8XUa4C8N5YBjbCQzRv39g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8eb769ba2d92c371f856ccb19f65ad94","width":480,"height":217}},"lazy":false},{"type":"text","content":"KEYTRUDA plus paclitaxel with or without bevacizumab is the first PD-1 inhibitor-based regimen to show a statistically significant improvement in OS regardless of PD-L1 status","length":175,"tagName":"p","attribs":{}},{"type":"text","content":"Results from the final analysis of the Phase 3 KEYNOTE-B96 trial to be presented during a Best Oral Session at the European Society of Gynaecological Oncology 2026 Congress","length":172,"tagName":"p","attribs":{}},{"type":"text","content":"Positive EU CHMP opinion granted for KEYTRUDA plus paclitaxel with or without bevacizumab in certain adults with PD-L1 (CPS ≥1) platinum-resistant ovarian carcinoma who have received one or two prior systemic treatment regimens","length":227,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., February 27, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, showing that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab significantly improved overall survival (OS), a key secondary endpoint, for patients with platinum-resistant recurrent ovarian cancer regardless of PD-L1 status versus paclitaxel with or without bevacizumab alone, the most active standard of care control arm for patients who are bevacizumab-eligible. These data will be presented for the first time today during a Best Oral Session at the European Society of Gynaecological Oncology (ESGO) 2026 Congress (abstract #526).","length":851,"tagName":"p"},{"type":"text","content":"As previously reported at the European Society for Medical Oncology (ESMO) Congress 2025, KEYTRUDA plus paclitaxel with or without bevacizumab met its primary endpoint of progr...